KBC

KBC Group NV, headquartered in Brussels, Belgium, is a bank-insurance firm that offers integrated financial services primarily to retail clients, private banking, small and medium-sized enterprises, and mid-cap clients. The company provides a wide range of products, including demand deposits, savings accounts, home and mortgage loans, consumer finance, and SME funding. Additionally, KBC offers life and non-life insurance, asset management, cash management, trade finance, leasing, and corporate finance services. The firm operates numerous branches across Belgium, the Czech Republic, Hungary, Bulgaria, and Ireland, serving customers through various channels, including agents and electronic platforms. KBC Private Equity, a subsidiary of KBC Group, focuses on providing development capital and financing buy-outs for medium-sized companies, with a commitment to becoming a leading private equity provider in its home markets. Established in 1935, KBC Group has evolved to meet the diverse financial needs of its clientele while maintaining a strong presence in Central and Eastern Europe.

Daniel Falque

CEO, Belgium Business Unit

John Hollows

CEO, Czech Republic Business Unit and Member of the Executive Committee

Pavel Kavánek

CEO, Czech Republic Business Unit

Thomas Leysen

Chairman of the Board

Gerd Smeets

Investment Director

Past deals in Belgium

Stellar Labs

Seed Round in 2020
The revolution in learning, the skills of tomorrow trained today. At Stellar Labs we have found a way to solve the skills gap in the tech sector. A science based way, backed by research to achieve the best performance and return on investment. Learners are energised and engaged to quickly master high-demand technical skills and capabilities. We focus on results-driven solutions to help the technical workforce thrive today and lead the change into tomorrow. The technology market is booming, but the industry faces a global talent shortage. Stellar Labs provides the answer – and the competitive advantage.

ArtiQ

Seed Round in 2019
ArtiQ NV is a Belgian company founded in 2019 as a spin-off from the University of Leuven, specializing in artificial intelligence-driven medical software for respiratory care. The company has developed ArtiQ|PFT, a software solution that automates the processing of pulmonary function test data, facilitating the diagnosis, treatment, and monitoring of lung diseases. By leveraging AI technology, ArtiQ|PFT enhances the accuracy and efficiency of interpreting test results, providing healthcare professionals with insights into disease patterns and probabilities, as well as recommendations for patient management. With a focus on improving the diagnostic environment for lung diseases, ArtiQ aims to serve as a reliable partner for medical practitioners and contribute positively to patient outcomes and the healthcare system.

Joyn Belgium

Seed Round in 2017
Joyn Belgium operates a customer engagement platform that enhances the relationship between merchants and their customers. The platform allows users to utilize a loyalty card that enables them to earn rewards points while shopping at their preferred stores. Customers can redeem these points for various benefits, including discounts and prizes, fostering loyalty and repeat business. By integrating the efforts of numerous local merchants, Joyn provides a unified app that offers unique advantages to customers, encouraging them to return to participating businesses. This approach not only supports merchants in growing their customer base but also helps consumers discover valuable rewards and promotions from a diverse range of local retailers.

Go Vocal

Seed Round in 2016
CitizenLab NV is a civic engagement software company based in Brussels, Belgium, founded in 2015. The company offers a platform designed for city governments to enhance citizen participation in decision-making processes. Its features enable two-way communication between local authorities and residents, allowing citizens to propose and discuss ideas, vote on them, and provide feedback through polls and surveys. The platform also includes tools for city managers to visualize decision-making through timelines and maps, as well as analytics and reporting features to facilitate informed decision-making. By promoting transparency and collaboration, CitizenLab aims to make governance more democratic and effectively engage citizens in shaping their communities.

Pronota

Series C in 2012
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

Pronota

Series B in 2009
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

Aristo Music Technology

Venture Round in 2008
Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.

Okapi Sciences

Series A in 2008
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Movetis

Series A in 2007
Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.

Ablynx

Series C in 2006
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.

Pronota

Series A in 2006
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

HSBC Dewaay S.A.

Acquisition in 2005
HSBC Dewaay SA is a privately held company offers private banking and trustee services. It services include cash management, discretionary portfolio management, and patrimonial advisory services.

Almanij NV

Acquisition in 2005
Almanij NV engages in banking, insurance, and investment activities; and the provision of specialized financial services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.